Friedrich Graf - Jan 3, 2023 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
Chief Medical Officer
Signature
/s/ Friedrich Graf Finckenstein
Stock symbol
IOVA
Transactions as of
Jan 3, 2023
Transactions value $
-$67,351
Form type
4
Date filed
1/5/2023, 07:57 PM
Previous filing
Jun 16, 2022
Next filing
Jan 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IOVA Common Stock Options Exercise $0 +19.7K +152.86% $0.00 32.6K Jan 3, 2023 Direct F1
transaction IOVA Common Stock Tax liability -$67.4K -11K -33.84% $6.11 21.5K Jan 3, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOVA Restricted Stock Units Options Exercise $0 -19.7K -100% $0.00* 0 Jan 3, 2023 Common stock 19.7K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is the second and final vesting of the restricted stock units ("RSUs") issued on June 14, 2021.
F2 Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities.
F3 Represents the common stock remaining after deducting the common stock withheld for taxes.
F4 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F5 As of December 31, 2022, the remaining RSUs have fully vested and were settled on January 3, 2023.